1) Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fas-so M, Niger M, Pietrantonio F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P. Gut. 2021 Aug 25:gutjnl-2021-324420. [IF: 19.819].
2) Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM, Le TBU, Prawira A, Ho RZW, Huynh H.Hepatol Int. 2021 Jul 31. [IF: 6.047]
3) A Phase II Single Arm, Single Centre Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinoma– CA 209-678. David Tai, Kelvin Loke, Apoorva Gogna, Neslihan Arife Kaya, Sze Huey Tan, Tiffany Hennedige, Da-vid Ng, Farah Irani, Joycelyn Lee, Jia Qi Lim, Chow Wei Too, Matthew C.H. Ng, Chee Kian Tham, Justina Lam, Si Lin Koo, Hui Shan Chong, George Boon-Bee Goh, Hian Liang Huang, Nanda Venkatanarasimha, Richard Lo, Prof. Pierce K.H. Chow, Prof. Brian K. P. Goh, Prof. Alexander Chung, Han Chong Toh, Prof. Choon Hua Thng, Prof. Tony K.H. Lim, Joe Yeong, Weiwei Zhai, Chung Yip Chan, Su Pin Choo. Lancet Gastroenterology and Hepatology (Manuscript accepted). [IF 18.486].
4) Efficacy and Tolerability of Novel Regimen of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Robin K. Kelley; Bruno Sangro; William Harris; Masafumi Ikeda; Takuji Okusaka; Yoon-Koo Kang; Shukui Qin; David W. M. Tai; Ho Yeong Lim; Thomas Yau; Wei-Peng Yong; Ann-Lii Cheng, MD; Antonio Gasbarrini; Silvia Damian; Jordi Bruix; Mitesh Borad; Johanna Bendell; Tae-You Kim; Na-than Standifer; Philip He; Mallory Makowsky; Alejandra Negro; Masatoshi Kudo and Ghassan K. Abou-Alfa. Journal of Clinical Oncol 2021 Jul 22:JCO2003555. [IF: 44.544].
5) Non-Terminally Exhausted Tumor-Resident Memory HBV-specific T Cell Responses Corre-late with Relapse-Free Survival in Hepatocellular Carcinoma
Yang Cheng, Bavani Gunasegaran, Harsimran D. Singh, Charles-Antoine Dutertre, Chiew Yee Loh, Jia Qi Lim, Jeremy Chase Crawford, Hong Kai Lee, Xiaomeng Zhang, Bernett Lee, Etienne Becht, Joe Yeong, Wan Jun Lim, Jerry K.Y. Chan, Florent Ginhoux, David Tai, Jinmiao Chen, Seng Gee Lim, Weiwei Zhai, Su Pin Choo, Evan W. Newell. Immunity. 2021 Aug 10;54(8):1825-1840 [IF: 22.553]
6) Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Mul-ticenter Retrospective Study.
Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Liver Cancer. 2021 Apr;10(2):107-114. [IF: 11.740].
7) Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Intermediate and Advanced/Relapsed Hepatocellular Carcinoma: A TOS-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Published online 06 JAN 2020 - Ann Oncol (2020) L.T. Chen, E. Martinelli, A.L. Cheng, G. Pentheroudakis, S. Qin, G.S. Bhattacharyya, M. Ikeda, H.Y. Lim, G.F. Ho, S.P. Choo, Z. Ren, H. Malhotra, M. Ueno, B.Y. Ryoo, T.C. Kiang, D. Tai, A. Vogel, A. Cervantes, S.N. Lu, C.J. Yen, Y.H. Huang, S.C. Chen, C. Hsu, Y.C. Shen, J. Tabernero, Y. Yen, C.H. Hsu, T. Yoshino, J.Y. Douillard. [IF: 32.976].
8) Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsive-ness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH.J Immunother Cancer. 2020 Aug;8(2):e000987. [IF:13.751]
9) Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, Goldstein D, Burge M, Cooray P, Nagrial A, Tebbutt NC, Thomson B, Nikfarjam M, Harris M, Haydon A, Lawrence B, Tai DWM, Simons K, Lennon AM, Wolfgang CL, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Ann Oncol. 2019 Sep 1;30(9):1472-1478. [IF: 32.976]
10) Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroen-docrine neoplasm (GEPNEN) in a multi-ethnic Asian institution
Tai D, Tan SH, Tan D, Loke K, Ng D, Yan S, Hwang J, Lim KH, Loh LM, Kek PC, Goh B, Lee SY, Chung AYF, Ong S. Neuroendocrinology. 2018 Nov 6. doi: 10.1159/000495140. [IF: 4.271]
